|
1
|
Rosenberg SA: Progress in human tumour
immunology and immunotherapy. Nature. 411:380–384. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bour-Jordan H and Blueston JA: CD28
function: A balance of costimulatory and regulatory signals. J Clin
Immunol. 22:1–7. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Gool SW, Barcy S, Devos S,
Vandenberghe P, Ceuppens JL, Thielemans K and de Boer M: CD80
(B7-1) and CD86 (B7-2): Potential targets for immunotherapy. Res
Immunol. 146:183–196. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slavik JM, Hutchcroft JE and Bierer BE:
CD28/CTLA-4 and CD80/CD86 families: Signaling and function. Immunol
Res. 19:1–24. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakajima A and Azuma M: Costimulatory
molecules in autoimmunity: Role of CD28/CTLA4-CD80/CD86. Nihon
Rinsho. 55:1419–1424. 1997.(In Japanese). PubMed/NCBI
|
|
6
|
Krummel MF and Allison JP: CTLA-4
engagement inhibits IL-2 accumulation and cell cycle progression
upon activation of resting T cells. J Exp Med. 183:2533–2540. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soskic B, Qureshi OS, Hou T and Sansom DM:
A transendocytosis perspective on the CD28/CTLA-4 pathway. Adv
Immunol. 124:95–136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Darcy PK, Neeson P, Yong CS and Kershaw
MH: Manipulating immune cells for adoptive immunotherapy of cancer.
Curr Opin Immunol. 27:46–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Margolin KA, Negrin RS, Wong KK,
Chatterjee S, Wright C and Forman SJ: Cellular immunotherapy and
autologous transplantation for hematologic malignancy. Immunol Rev.
157:231–240. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schmeel LC, Schmeel FC, Coch C and
Schmidt-Wolf IG: Cytokine-induced killer (CIK) cells in cancer
immunotherapy: Report of the international registry on CIK cells
(IRCC). J Cancer Res Clin Oncol. 141:839–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mesiano G, Todorovic M, Gammaitoni L,
Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F,
Piacibello W, Aglietta M and Sangiolo D: Cytokine-induced killer
(CIK) cells as feasible and effective adoptive immunotherapy for
the treatment of solid tumors. Expert Opin Biol Ther. 12:673–684.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chung MJ, Park JY, Bang S, Park SW and
Song SY: Phase II clinical trial of ex vivo-expanded
cytokine-induced killer cells therapy in advanced pancreatic
cancer. Cancer Immunol Immunother. 63:939–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang XF, Ma DC, Ding ZY, Liu ZZ, Guo F,
Liu L, Yu HY, Han YL and Xie XD: Autologous cytokine-induced killer
cells therapy on the quality of life of patients with breast cancer
after adjuvant chemotherapy: A prospective study. Zhonghua Zhong
Liu Za Zhi. 35:764–768. 2013.PubMed/NCBI
|
|
15
|
Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang
N, An X, Yu J, Li H and Ren X: A randomized phase II study of
autologous cytokine-induced killer cells in treatment of
hepatocellular carcinoma. J Clin Immunol. 34:194–203. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhong R, Han B and Zhong H: A prospective
study of the efficacy of a combination of autologous dendritic
cells, cytokine-induced killer cells, and chemotherapy in advanced
non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Robert L, Harview C, Emerson R, Wang X,
Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC and
Ribas A: Distinct immunological mechanisms of CTLA-4 and PD-1
blockade revealed by analyzing TCR usage in blood lymphocytes.
Oncoimmunology. 3:e292442014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qureshi OS, Zheng Y, Nakamura K, Attridge
K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z,
et al: Trans-endocytosis of CD80 and CD86: A molecular basis for
the cell-extrinsic function of CTLA-4. Science. 332:600–603. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Catalfamo M, Tai X, Karpova T, McNally J
and Henkart PA: TcR-induced regulated secretion leads to surface
expression of CTLA-4 in CD4+CD25+ T cells.
Immunology. 125:70–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chambers BJ, Salcedo M and Ljunggren HG:
Triggering of natural killer cells by the costimulatory molecule
CD80 (B7-1). Immunity. 5:311–317. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geldhof AB, Moser M, Lespagnard L,
Thielemans K and De Baetselier P: Interleukin-12-activated natural
killer cells recognize B7 costimulatory molecules on tumor cells
and autologous dendritic cells. Blood. 91:196–206. 1998.PubMed/NCBI
|
|
22
|
Stojanovic A, Fiegler N, Brunner-Weinzierl
M and Cerwenka A: CTLA-4 is expressed by activated mouse NK cells
and inhibits NK Cell IFN-γ production in response to mature
dendritic cells. J Immunol. 192:4184–4191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quezada SA, Peggs KS, Curran MA and
Allison JP: CTLA4 blockade and GM-CSF combination immunotherapy
alters the intratumor balance of effector and regulatory T cells. J
Clin Invest. 116:1935–1945. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Egen JG, Kuhns MS and Allison JP: CTLA-4:
New insights into its biological function and use in tumor
immunotherapy. Nat Immunol. 3:611–618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamaguchi T and Sakaguchi S: Regulatory T
cells in immune surveillance and treatment of cancer. Semin Cancer
Biol. 16:115–123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakaguchi S: Naturally arising
Foxp3-expressing CD25+CD4+ regulatory T cells
in immunological tolerance to self and non-self. Nat Immunol.
6:345–352. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Friedline RH, Brown DS, Nguyen H, Kornfeld
H, Lee J, Zhang Y, Appleby M, Der SD, Kang J and Chambers CA: CD4+
regulatory T cells require CTLA-4 for the maintenance of systemic
tolerance. J Exp Med. 206:421–434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Josefowicz SZ, Lu LF and Rudensky AY:
Regulatory T cells: Mechanisms of differentiation and function.
Annu Rev Immunol. 30:531–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Onishi Y, Fehervari Z, Yamaguchi T and
Sakaguchi S: Foxp3+ natural regulatory T cells
preferentially form aggregates on dendritic cells in vitro and
actively inhibit their maturation. Proc Natl Acad Sci USA. 105:pp.
10113–10118. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Read S, Greenwald R, Izcue A, Robinson N,
Mandelbrot D, Francisco L, Sharpe AH and Powrie F: Blockade of
CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in
vivo. J Immunol. 177:4376–4383. 2006. View Article : Google Scholar : PubMed/NCBI
|
